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We compared 14 molecular assays for their ability to detect theMycobacterium tuberculosis complex in bronchoalveolar lavage
fluid samples. Three approaches were followed. First, by using DNA fromMycobacterium bovis BCG, we determined the detec-
tion limits of the assays using routine molecular methods. Second, in order to determine the analytical sensitivities of the assays,
we added one of fourM. tuberculosis isolates with various numbers of the insertion sequence IS6110 toN-acetyl-L-cysteine
(NALC)-NaOH-treated bronchoalveolar lavage fluid samples in dilutions of 1:10 to 1:10,000,000. Third, intertest variabilities
were measured and defined by the standard deviations for the quantitation cycle (Cq) values of three positive test results per di-
lution per assay. The 14 assays tested had similar analytical sensitivities, except forGeneXpert, which had an analytical sensitivity that
was 10- to 100-fold lower than that of the other assays. TheMPMTB/NTMtest and the in-house TaqMan-10 revealed the best perfor-
mances for the detection limit andhad the highest analytical sensitivities.Most of the tests performedwell regarding detection limit
and analytical sensitivity for the detection of theM. tuberculosis complex in serial dilutions, and the differenceswere small. TheMP
MTB/NTMand the in-house TaqMan-10 assays revealed the best, andGeneXpert theworst, overall performances.
In 2011, 6.2 million patients were diagnosed with tuberculosis(TB) worldwide and reported this to the national tuberculosis
control programs (NTP) (1). Control of this high-burden disease
heavily depends on improved rapid diagnosis and optimal treat-
ment. Real-time (RT)-PCR is the standard DNA amplification
technique currently used in TB laboratories. In a short time span,
a substantial number of commercial nucleic acid amplification
tests for Mycobacterium tuberculosis complex (MTC) infections
have become available. However, these assays have not been com-
pared in a systematic manner. The clinical sensitivity of a part of
the assays has been reported in only a few studies, using culture
positivity and/or clinical diagnosis as the “gold standard” (2–6).
The insertion sequence IS6110 has long been appreciated as a
target in themolecular detection of theM. tuberculosis complex in
clinical material, and it is the most abundant IS element in the
genome of M. tuberculosis. However, among clinical isolates
worldwide, the number of IS6110 copies in the genome of M.
tuberculosis varies from 0 to 25, potentially influencing the detec-
tion limits of related assays (7–10).
In this study, we compared the analytical performances of 14
assays for the molecular detection of MTC in three different ap-
proaches. We hypothesized that not all assays would have equally
good analytical sensitivities and that the analytical sensitivity of
assays targeting IS6110 would depend on the number of target
copies in the genomes ofM. tuberculosis strains studied.We there-
fore compared IS6110-targeting tests with those not targeting this
element or that explored unknown or undisclosed targets.
MATERIALS AND METHODS
Assays. Fourteen assays were compared, 9 of which are commercially
available (Table 1). The assays were performed according to the instruc-
tions of each manufacturer. The cutoff values of the assays applied were
those provided by the manufacturers.
Internal transcribed sequence high-resolution melting. Amplifica-
tion ofM. tuberculosis complexDNAwas done using a real-time PCRwith
a high-resolution melting (HRM) mix (HRM master mix; Roche Diag-
nostics Nederland BV, Almere, the Netherlands). The amplification of a
part of the internal transcribed spacer (ITS) spacer of 200 to 330 bp, which
is located between the 16S and 23S gene spacer, was performed with the
primers tb-ITS-fw and tb-ITS-re-rev1. For this amplification, no probe is
used, so the sensitivity of this test solely depends on the primers. The
melting curve results of theM. tuberculosis complex control were recorded
as positive if the DNA denatured between 89 and 90°C. Therefore, when
testing forM. tuberculosis, the results were considered positive whenmelt-
ing curves were between 89 and 90°C. Subsequently, the quantitation
cycle (Cq) values were used for further calculation (11).
M. tuberculosis complex control. The Mycobacterium bovis BCG
strain is normally used as an internal control for the in-house PCR assay,
which is used in our laboratory and contains a single copy of IS6110 (12,
13). One colony of thisM. bovis BCG strain was added to PrepMan solu-
tion (PrepMan Ultra sample preparation reagent; Applied Biosystems,
Nieuwerkerk aan de IJssel, the Netherlands) to prepare a turbid suspen-
sion. This suspension was incubated for 10min at a temperature of 100°C
to release DNA. Thereafter, a 1:10 dilution was prepared in Tris-EDTA
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(TE) buffer. This extracted DNAwas used in all the PCRs for determining
the detection limits (DLs).
Isolates. FourM. tuberculosis isolates with a known number of IS6110
copies were selected from theM. tuberculosis isolate collection at the Na-
tional Tuberculosis Reference Laboratory, each containing 1, 5, 10, or 20
copies of the IS6110 element. The four isolates were cultured to prepare a
large set of identical bronchoalveolar lavage fluid (BALF) samples with
quantified numbers of mycobacteria. Cultures were done in the MGIT
Bactec 960 system (Becton, Dickinson, Sparks, MD).
Specimen processing. We pooled redundant BALF specimens ob-
tained from routine bronchoscopy procedures performed at several hos-
pitals on various patients not suffering fromanyMycobacterium infection.
The BALF specimens were combined to a total volume of 800 ml and
mechanically liquefied and homogenized with N-acetyl L-cysteine
(NALC)-sodium hydroxide (NaOH) (14). After centrifugation, the
treated BALF combination was concentrated, and this resulted in a total
volume of 80 ml. The concentrated NALC-NaOH-treated BALF mixture
was checked to be negative for MTC using the in-house IS6110 RT-PCR.
Strain processing. Cultures were prepared and heat killed (40 min at
115°C). Heat killing of the strains was performed before and after mixing
the bacteria with the NALC-NaOH-treated BALFmixture. The difference
in the quantitation cycle (Cq) values in the in-house IS6110 RT-PCR for
one strain between the two processes was never higher than 0.57 (1:10
dilution from anM. tuberculosis isolate with one IS6110 copy).
Serial dilution and DNA isolation. A fixed number of heat-killedM.
tuberculosis organismswas added to theNALC-NaOH-treated BALFmix-
ture. Dilutions of 1:10 to 1:10,000,000 were made of this suspension, and
the dilutions were frozen at 80°C in portions of 250 l. From these
dilutedM. tuberculosis suspensions, 200 l was extracted with NucliSens
easyMAG (bioMérieux, Boxtel, theNetherlands). The extractedDNAwas
tested in the in-house IS6110 RT-PCR for reproducibility and was further
used in a comparison of all the assays.
The reproducibilities of the DNA extraction and the in-house IS6110
RT-PCR were tested on the frozen material at three different time points,
in duplicate. In this way, the means and coefficients of variance (CVs) for
the Cq values of the eight different dilutions from the four isolates in
duplicate were calculated. The difference in the mean Cq value was never
higher than 1.08, and the CV was never higher than 2%.
Assay comparison.The analytical sensitivities of the assays were com-
pared in two different ways. First, we determined the detection limit (DL).
For this purpose, we used a dilution series of theDNAof theM. bovisBCG
strain that is used as a control in routine diagnostics. TheDNAwas diluted
in TE buffer. The assay was tested in triplicate for each dilution. A higher
dilution of the suspensionwas recorded as positive only if it tested positive
three times in the respective assay. After a first negative result, the dilu-
tions between the first negative dilution and the last positive dilution were
tested as well.
Second, we determined the analytical sensitivity that captures both the
process of DNA extraction and the use of the extracted DNA from theM.
tuberculosis serial dilutions in the BALF mixture in RT-PCR. Again, the
test of a higher dilution was recorded as positive only if the three results
were all positive.
Additionally, as a thirdmethod of comparison, the intertest variability
of the assays was assessed. The intertest variability of each assay was de-
fined using the standard deviation (SD). The SDwas calculated for the Cq
values of the three positive test results per dilution per assay, using the
results from theM. tuberculosis serial dilutions in BALF samples and not
the results using theM. bovisBCG strain diluted in TE buffer for detection
limit determination.
Statistics.Descriptive statistical methods are provided in themethod-
ological sections above.
RESULTS
Detection limit. We used serial dilutions of M. bovis BCG DNA
that is used routinely as a positive control in molecular assays and
TABLE 1 Molecular assays tested in order of their target
Target Assay name and description (short name used in article) Assay manufacturer (reference)
IS6110 Exptl RT-PCR: 5 l DNA input and Roche master mix (in-house Roche-5) Roche Diagnostics Nederland BV, Almere, the
Netherlands (21)
IS6110 In-house RT-PCR IS6110: 5 l DNA input and TaqMan universal PCR
master mix,AmpErase UNG (in-house TaqMan-5)
Applied Biosystems, Nieuwerkerk aan de Ijssel, the
Netherlands (21)
IS6110 In-house RT-PCR IS6110: 10 l DNA input and TaqMan universal PCR
master mix,AmpErase UNG (in-house TaqMan-10)
Applied Biosystems (21)
IS6110 MTB Q-PCR Alert kit detection ofMycobacterium tuberculosis DNA
(Lucron)
Lucron ELITechGroup, Dieren, the Netherlands
IS6110 RealAccurateMycobacterium tuberculosis PCR kit (PathoFinder) PathoFinder BV, Maastricht, the Netherlands
IS6110 MTB real-time kit for detection ofMycobacterium tuberculosis complex
(MP MTB kit)
Sacace Biotechnologies, Como, Italy, provided by
MP Products, the Netherlands
IS6110 MTB/NTM kit: multiplex MTC real-time PCR kit: AmpliSens MTC-FRT
PCR kit (MP MTB/NTM)
InterLabService (ILS), Moscow, Russia, provided
by MP Products, the Netherlands
IS6110 Myco Direct 1.7, DNA based identification ofMycobacterium tuberculosis
complex (MTUB) and other Mycobacteria (MOT) LCD array kit
(Chipron)a
Chipron, GmbH, Berlin, Germany
16S-23S rRNA gene Internal transcribed sequence high-resolution melting (ITS-HRM) and
Roche HRMmaster mix (in-house ITS-HRM)
Roche Diagnostics Nederland BV (11)
16S rRNA of bp 584 Cobas TaqMan MTB test CTMMTB (Cobas) Roche Diagnostics Nederland BV
Direct repeat region of
M. tuberculosis
Spoligotyping (spoligotyping)b Homemade (22)
rpoB gene GeneXpert MTB/RIF assay (GeneXpert) Cepheid Benelux, Apeldoorn, the Netherlands (23)
Not disclosed by the
manufacturer
AccuPower MTB real-time PCR kit (Goffin MTB) Bioneer, South Korea, provided by Goffin, the
Netherlands
Not disclosed by the
manufacturer
AccuPower MTB&NTM real-time PCR kit (Goffin MTB/NTM) Bioneer, South Korea, provided by Goffin
a The target-specific capture probes and the capture probes for the external control sequence Ctrl-EX1 together form a cross or a “” sign.
b Recorded positive if3 spacers are present.
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that contains one copy of IS6110 per genome. When comparing
the detection limits, we considered the assay with a positive result
at the greatest dilution to have the lowest detection limit. The
results for assays targeting IS6110 and for assays using other ge-
netic targets, or for tests with a target not disclosed by the manu-
facturer, are shown in Fig. 1. Four tests had the same low detection
limit: these assays positively identifiedMTC at up to a 1:100 DNA
dilution. The detection limit, independent of the type of target,
was highest in the Lucron, PathoFinder, and in-house ITS-HRM
assays. These assays amplified up to a 1:10 DNA dilution.
The detection limit of GeneXpert assay could not be calculated
because this assay can be performed only with clinical intact ma-
terial and not with purified DNA.
Analytical sensitivity in serial dilutions with different num-
bers of IS6110 elements.The second approach for comparing the
assays was to analyze the DNA from the different M. tuberculosis
strains with various numbers of IS6110 copies, serially diluted in a
BALF mixture. The results are shown in Fig. 2.
Of the assays targeting IS6110 in the dilutions with the strain
carrying one copy of IS6110, the in-house Roche-5 assay was able
to detect M. tuberculosis DNA to a 1:10,000 dilution. All other
assays were able to detect M. tuberculosis DNA to a 1:100,000 di-
lution, and the MP MTB was even able to detect M. tuberculosis
DNA to a 1:1,000,000 dilution.
The highest analytical sensitivity with the dilution of the five-
IS6110-copy strain was found for the PathoFinder assay, which
detected M. tuberculosis DNA to a 1:1,000,000 dilution. All other
assays detectedM. tuberculosis DNA to a 1:100,000 dilution.
With dilutions of the 10-IS6110-copy strain, both the in-house
Roche-5 and the in-house TaqMan-5 assays detectedM. tubercu-
losis DNA to a 1:100,000 dilution of. All other assays were able to
detectM. tuberculosis DNA to a 1:1,000,000 dilution.
With dilutions of the 20-IS6110-copy strain, the MP MTB/
NTM and in-house TaqMan-10 assays were able to detect M. tu-
berculosisDNAup to a 1:10,000,000 dilution. All other assays were
able to detectM. tuberculosis DNA to a 1:1,000,000 dilution.
All assays except the MP MTB had increased analytical sensi-
tivity for multicopy IS6110 strains.
The analytical sensitivities of the assays not targeting IS6110
yielded comparable results for the assays and were, as expected,
not dependent on the number of IS6110 copies per genome in the
strains. An exception was the GeneXpert assay, which had an an-
alytical sensitivity that was 10-fold lower than that of the other
assays. The analytical sensitivity of the Goffin MTB/NTM assay
was higher if 10 IS6110 copies were present in theM. tuberculosis
strain tested. For dilutions of the strain with 20 copies of IS6110,
theCobas, GoffinMTB, and spoligotyping tests were able to detect
M. tuberculosis DNA at a one-log-higher dilution than for strains
containing fewer copies of IS6110.
Intertest variability of the molecular assays. The intertest
variability of each assay was defined using the standard deviation
(SD). The SDwas calculated for the Cq values of the three positive
test results per dilution per assay, using results from theM. tuber-
culosis serial dilutions in the BALF mixture.
The results of three different dilutions are depicted in Tables 2
to 5. The first results are for the undiluted series. The second
results are for a dilution of 1:10,000, the dilution in which the first
assay (in-house Roche-5) reached its analytical sensitivity (Fig. 2).
The last results are for the dilutions at which the separate assays
reached the analytical sensitivity (AS) (which was a different level
depending on the assay).
For all assays, the intertest variability was within a standard
deviation of 2. Only a disproportionately high intertest variability
FIG 1 Comparison of detection limits using dilution series of the DNA ofM. bovis BCG that is used as positive control in routine diagnostics and contains one
copy of IS6110. The x axis shows the dilution, which was recorded as positive if the assay tested positive three times; the longer the black bar, the better the test
performance. The y axis shows the assays tested. The first eight assays target IS6110. Three other assays do not target this insertion sequence, but target another
known target (see Table 1). For the two Goffin assays, the manufacturer does not disclose the target.
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(SD, 3.2) was found for the MPMTB/NTM assay for the 1:10,000
dilutions containing one copy of IS6110.
Calculating the intertest variability was not possible for the
GeneXpert assay as a sole test, due to its five probes. All probes had
their own Cq values and had to give a positive result to score the
overall result as positive. After the results for the GeneXpert assay
in this laboratory became known, we retested GeneXpert in an-
other laboratory. We did this to calculate the intertest variability
of GeneXpert with isolates at dilutions of 1:1,000 and 1:10,000 in
triplicate. The results of the intertest variability of the probes
themselves from both laboratories are shown in Table 5.
DISCUSSION
This is the first study to describe a direct comparison of 14 differ-
ent PCR assays for themolecular detection ofM. tuberculosis com-
plex in clinical material. We assessed the sensitivities of the assays
using two different approaches, as well as studied intertest vari-
ability. All assays performed equally well regarding detection limit
and analytical sensitivity for the detection of serial dilutions ofM.
tuberculosis suspensions with various numbers of IS6110 ele-
ments; the positive exceptions were the in-house TaqMan-10 and
the MPMTB/NTM assays. A more clear discrepancy between the
results in both approaches was observed for the Lucron and
PathoFinder tests. The intertest variability of all assays tested was
within 2 standard deviations, and their performances were thus
comparable.
For the first comparison approach, assays targeting IS6110
showed the lowest detection limits. In a comparison of the overall
detection limits for all assays with the analytical sensitivities, all as-
says performed similarly, except for the Lucron and PathoFinder
assays. An explanation for this might be the lower DNA input in
these two assays (5 l DNA) compared to that of the best-per-
forming assays (10l DNA). Another possible explanation is that
the DNA extraction method (PrepMan for the DL and easyMAG
for the analytical sensitivity) yields differences in the purity of the
DNA, and less-pure DNA might yield a higher detection limit
(15). To our knowledge, no direct comparison of the PrepMan
and easyMAG extraction procedures forM. tuberculosis has been
performed so far.
All assays targeting IS6110 had increasing analytical sensitivity
with an increasing number of IS6110 copies in the strains tested,
which is in accordance with our hypothesis. Only the MP MTB
assay yielded unexpected results. This kit had an analytical sensi-
tivity with the dilution of the one-copy IS6110 strain, which was
better compared to that of the five-copy IS6110 strain. Both in-
house TaqMan-10 and MP MTB/NTM had the lowest detection
limits as well as the highest analytical sensitivities with the dilution
of the 20-copy IS6110 strain. These were the only assays yielding
fully concordant results between the detection limit analysis and
the analytical sensitivity. Assays not targeting IS6110 yielded com-
parable results with both approaches. All assays had a better ana-
lytical sensitivity at the dilutions of the 20-IS6110-copy strain,
except for the in-house ITS-HRMandGeneXpert assays. Since the
analytical sensitivity of the GoffinMTB/NTM assay, which has an
FIG 2 Comparison of analytical sensitivities of the assays tested with dilutions of DNA isolated from strains with various numbers of IS6110 copies in BALF
samples. The x axis shows the dilution,whichwas recorded as positive if an assay tested positive three times for the specific assay. The y axis shows the assays tested.
The first eight assays target IS6110. The next four assays are known to target IS6110. For the two Goffin assays, the manufacturer does not disclose the target.
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undisclosed molecular target, performed better if more IS6110
copies were present in the test strain, this assay probably also tar-
gets IS6110.
Intertest variability was the third study subject and was tested
on the basis of triplicate results from the serial dilutions in a BALF
mixture. Overall, no assay was found to under- or outperform
another. Nevertheless, the highest intertest variability of the as-
says, independent of their target and the tested dilution,was found
with theMPMTB/NTMassay at the 1:10,000 dilutions.One of the
three runs of this assay had a Cq value at this dilution, which is
used as cutoff value by the manufacturer. The result was still pos-
itive but had a difference of 5 Cq values compared to those of the
other two runs. After the results were analyzed, this was the only
divergent run of all the runs tested for each PCR assay included,
for which we found no obvious laboratory-related explanation.
Tests that have greater intertest variability obviously are more
prone to produce more divergent results.
We checked our methodology in this study regarding the even
distribution ofM. tuberculosis in the BALF samples, the procedure
of heat killing of the strains, and the efficacy ofDNA isolation. The
homogenized and concentrated NALC-NaOH-treated BALF
mixture was checked to be negative for MTC using the in-house
IS6110RT-PCR. Comparing the amplification of DNAbefore and
TABLE 2 Intertest variability of assays targeting IS6110, calculated by
standard deviation of the Cq values
Assay Dilution
Result with IS6110 copy no. of:
1 5 10 20
Expt 5a Undiluted 0.19 0.29 0.06 0.07
1:10,000 0.26 0.41 0.06 0.16
ASb (1:10,000) 0.26 1.53 0.46 1.08
In-house TaqMan-5 Undiluted 0.04 0.39 0.04 0.01
1:10,000 0.12 0.08 0.07 0.05
AS 0.77 0.48 0.18 0.25
In-house TaqMan-10 Undiluted 0.07 0.05 0.02 0.13
1:10,000 0.10 0.02 0.07 0.03
AS 0.60 0.29 0.36 0.4
Lucron Undiluted 0.05 0.03 0.04 0.26
1:10,000 0.5 0.33 0.07 0.2
AS 1.21 0.14 0.44 0.61
PathoFinder Undiluted 0.03 0.01 0.08 0.02
1:10,000 0.43 0.10 0.05 0.04
AS 0.47 0.39 0.40 0.23
MP MTB Undiluted 0.4 0.30 0.07 0.07
1:10,000 0.09 0.22 0.16 0.10
AS 0 0.06 1.03 0.23
MP MTB/NTMa Undiluted 0.03 0.03 0.06 0.04
1:10,000 3.2 1.00 0.07 0.04
AS 0.57 0.27 0.69 0.39
a Assays with highest intertest variability according to the standard deviation (SD).
b AS, analytical sensitivity.
TABLE 3 Intertest variability of assays not targeting IS6110, calculated
by standard deviation of the Cq values
Assay Dilution
Result with IS6110 copy no. of:
1 5 10 20
In-house ITS-HRM Undiluted 0.04 0.06 0.06 0.06
1:10,000 0.25 0.61 0.64 0.15
AS 1.36 0.53 0.73 0.20
Cobas Undiluted 0.1 0.25 0.1 0.06
1:10,000 0.25 0.2 0.31 0.21
AS 0.46 1.06 0.72 1.93
TABLE 4 Intertest variability of assays with a target not disclosed by the
manufacturer, calculated by standard deviation of the Cq values
Assay Dilution
Result with IS6110 copy no. of:
1 5 10 20
Goffin MTB Undiluted 0.03 0.02 0.06 0.03
1:10,000 0.18 0.04 0.08 0.11
AS 0.97 0.43 0.23 0.20
Goffin MTB/NTM Undiluted 0.05 0.05 0.09 0.42
1:10,000 0.29 0.14 0.14 0.15
AS 1.15 0.40 0.82 0.47
TABLE 5 Intertest variability of the probes of GeneXpert, calculated by




Result with IS6110 copy no. of:
1 5 10 20
A Undiluted 1.2 2.0 2.8 1.1
Lab 1 1:1,000 1.0 0.7 1.0 1.4
Lab 2 1:1,000 NCa 2.7 1.5 8.2
Lab 1b 1:10,000 0.9 0.8 2.8 1.8
Lab 2 1:10,000 1.3 1.3 NDc 1.1
B Undiluted 1.4 2.1 2.9 1.6
Lab 1 1:1,000 1.0 0.7 1.1 1.3
Lab 2 1:1,000 NC 2.5 1.3 7.3
Lab 1 1:10,000 1.0 0.7 2.3 1.9
Lab 2 1:10,000 1.0 1.8 ND 1.0
C Undiluted 1.1 2.1 3.0 1.0
Lab 1 1:1,000 1.0 0.7 1.1 1.4
Lab 2 1:1,000 NC 2.7 1.4 8.3
Lab 1 1:10,000 0.9 0.8 2.3 1.7
Lab 2 1:10,000 1.3 1.6 ND 0.9
D Undiluted 1.1 1.7 2.8 1.0
Lab 1 1:1,000 1.1 0.6 1.0 1.3
Lab 2 1:1,000 NC 2.5 1.4 8.0
Lab 1 1:10,000 0.9 0.8 2.0 1.7
Lab 2 1:10,000 1.1 1.5 ND 1.1
E Undiluted 1.3 2.3 3.0 0.8
Lab 1 1:1,000 1.1 0.7 1.0 1.3
Lab 2 1:1,000 NC 2.8 1.6 ND
Lab 1 1:10,000 0.9 0.9 2.3 1.8
Lab 2 1:10,000 1.6 1.4 ND 1.2
a NC, one of the three runs gave an error and thus the interest variability could not be
calculated.
b GeneXpert reached its analytical sensitivity with a dilution of 1:10,000 in lab 1.
c ND, at least one run could not be detected; thus, the analytical sensitivity was not
reached at this dilution.
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after heat killing tested the influence of this crucial step on DNA
isolation and the even distribution of M. tuberculosis in BALF
samples. Furthermore, the reproducibility of the DNA isolation
was tested at three different time points. All differences in the Cq
values of the heating procedure and the reproducibility were be-
low the 0.5-log10 difference. A difference above this value is con-
sidered to be clinically relevant (16, 17). We therefore conclude
that our methodology of DNA isolation of the strains by using
heat-killed bacilli, the even distribution of MTC, and the repro-
ducibility was appropriate.
The focus of this study was on the analytical sensitivity of the
assays. A comparison of clinical sensitivities was not performed on
routine clinical samples, such as sputum, because the quantities of
these samples are normally low, especially after NALC-NaOH
treatment and homogenization of this material. Also, the distri-
bution ofM. tuberculosis DNA in sputum is generally not homo-
geneous. Therefore, a comparison of 14 PCR assays using sputum
samples is virtually impossible and would have yielded irrepro-
ducible sensitivity results for each assay. A benefit of our compar-
ison using one pool of BALF samples is that this is highly compa-
rable for each assay. This material was used to add cultured
bacteria in serial dilutions in order to mimic as much as possible
the clinical context for patients with difficult-to-diagnose TB. For
future evaluation of novel molecular assays to be compared under
the same conditions, this material has been stored at80°C.
In our current analysis comparing 14 assays, the GeneXpert
assay showed a lower analytical sensitivity than all other assays.
However, it is likely that after the suspension was heated, frozen,
and thawed, some of the bacterial cells were already lysed. As this
is the only assay purifying whole bacterial cells from clinical ma-
terial, this may have negatively influenced its performance in
comparison to the methods that directly isolate and purify DNA.
This hypothesis is a subject for further research, which is planned
for the near future. As the individualized probes of the GeneXpert
assay sometimes revealed intertest variability exceeding 2 stan-
dard deviations, we retested the GeneXpert intertest variability in
another laboratory with isolates that were kept at 80°C. In this
second laboratory, the intertest variability for the individualized
probes was even greater than in the first laboratory.
Our study also evaluated the dependence of the assays on the
number of IS6110 copies in the genome of the MTC species de-
tected in the BALF samples. It is known that especially in Asia,
IS6110 is absent in a considerable number of M. tuberculosis iso-
lates (18). In the Netherlands, over a 5-year period, the IS6110
element was absent in only 3 isolates of a total of 3,884 isolates. As
expected, our study showed that the assays targeting IS6110 in-
deed have a higher sensitivity with larger numbers of IS6110 cop-
ies. In any case, the results in PCR targeting IS6110 in MTC will
vary according to the number of targets present in the detected
bacteria, as now has been proven in this study.
Clinical sensitivity is widely used as a measure for evaluating
the performance of a PCR assay. The analytical sensitivity as used
in our study has, in contrast to clinical sensitivity, hardly been
used for comparing the performance of PCR assays (2–6). How-
ever, a comparison of data regarding clinical sensitivity must be
interpreted with caution because clinical sensitivity is calculated
by comparing results with culture results or with the clinical diag-
nosis. Comparing the clinical sensitivities of assays is important in
smear-negative culture-positive samples, as smear-positive but
culture-positive samples already are known to have high clinical
sensitivity due to a higher bacterial load (19, 20). Research focused
on comparing the clinical sensitivities of selected assays in smear-
negative culture-positive samples, using the same clinical speci-
mens, is therefore needed.
In conclusion, comparing the sensitivities of PCR assays is
most reliable by analyzing the analytical sensitivities and the de-
tection limits. The detection limitswere nearly identical compared
to the results of the analytical sensitivities in this study, except for
the results for the Lucron andPathoFinder assays. As expected, the
analytical sensitivity was better for strains with more copies of
IS6110 elements. GeneXpert had the lowest analytical sensitivity
and was at least 10-fold less sensitive than the other assays. In our
study, the in-house TaqMan-10 and MP MTB/NTM assays had
the lowest detection limits and the highest analytical sensitivities
while testing dilutions of the 20-IS6110-copy strain. Overall, in-
tertest variability was within 2 standard deviations and was com-
parable for all assays, except for the individualized probes of the
GeneXpert assay, which sometimes had intertest variability ex-
ceeding 2 standard deviations.
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